124 Results for "

Cdk5

" in MedChemExpress (MCE) Product Catalog:
Products (124)

124 Results for "Cdk5" in MCE Product Catalog:

56
56 Publications Verification
Cat. No.: HY-10492
CAS No.: 779353-01-4
Purity:  99.80%
Synonyms: SCH 727965
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-30237
CAS No.: 186692-46-6
Synonyms: Seliciclib; CYC202
Target:  

CDK

(R)-Roscovitine (Seliciclib) is an orally bioavailable, selective and BBB-permeable CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-10580
CAS No.: 667463-62-9
Purity:  99.31%
Synonyms: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052
Target:  

GSK-3 CDK Apoptosis

Research Areas:  

Cancer

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-10012
CAS No.: 602306-29-6
Purity:  99.91%
Target:  

CDK

Research Areas:  

Cancer

AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-12302
CAS No.: 142273-20-9
Purity:  98.20%
Synonyms: 9-Bromopaullone; NSC-664704
Target:  

CDK GSK-3

Research Areas:  

Cancer

Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712A
CAS No.: 1805789-54-1
Purity:  99.90%
Synonyms: CT7001 hydrochloride; ICEC0942 hydrochloride
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712
CAS No.: 1805833-75-3
Synonyms: CT7001; ICEC0942
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712B
Purity:  99.06%
Synonyms: CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712C
Purity:  98.60%
Synonyms: CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-14392
CAS No.: 53-85-0
Purity:  99.89%
Synonyms: DRB
Target:  

CDK Apoptosis

Research Areas:  

Cancer

5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis [5] .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-11009
CAS No.: 164658-13-3
Purity:  98.90%
Target:  

CDK PKC

Research Areas:  

Cancer

CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-13266
CAS No.: 1092443-52-1
Target:  

CDK Apoptosis

Research Areas:  

Cancer

BS-181 is a potent and selective CDK7 inhibitor (IC50=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC50 values of 880, 3000 and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 inhibits a panel of cancer cells growth (IC50=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 has the potential for the research of cancer therapy .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-18299A
CAS No.: 212844-53-6
Synonyms: NG-60
Target:  

CDK Autophagy Apoptosis

Research Areas:  

Cancer

Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-19807
CAS No.: 160807-49-8
Synonyms: Indirubin-3'-oxime
Target:  

GSK-3 CDK Lipoxygenase

Research Areas:  

Cancer

Indirubin-3'-monoxime is a potent GSK-3β inhibitor, and weakly inhibits 5-Lipoxygenase, with IC50s of 22 nM and 7.8-10 µM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC50s of 100 and 180 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15504
CAS No.: 784210-87-3
Purity:  99.70%
Target:  

CDK GSK-3 MEK JAK

Research Areas:  

Cancer

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15504A
CAS No.: 784210-88-4
Purity:  98.02%
Target:  

CDK GSK-3 MEK JAK

Research Areas:  

Cancer

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18299
CAS No.: 212844-54-7
Synonyms: NG 95
Target:  

CDK Parasite

Research Areas:  

Infection Cancer

Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC50s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC50>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117025A
CAS No.: 104264-80-4
Purity:  99.66%
Synonyms: Keramamine A hydrochloride
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-144117
CAS No.: 2775311-17-4
Purity:  98.04%
Target:  

CDK

Research Areas:  

Metabolic Disease

GFB-12811 is a high selective CDK5 inhibitor with an IC50 of 2.3 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108359
CAS No.: 237430-03-4
Purity:  99.85%
Synonyms: 9-Nitropaullone; NSC 705701
Target:  

CDK GSK-3 Apoptosis

Research Areas:  

Cancer

Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC50s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis in leukemia cell line .
loading...
    loading...